Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

Infectious Microbes & Diseases, published by Lippincott Williams & Wilkins, is a premier journal dedicated to the exploration and understanding of infectious diseases, microbiology, and epidemiology. With its focused scope and robust peer-review process, the journal aims to disseminate high-quality research that contributes to advancements in the field, making it an essential resource for researchers, healthcare professionals, and students alike. Established in 2019, it has quickly gained recognition, achieving a Q3 rating in categories such as Epidemiology, Infectious Diseases, and Medical Microbiology in 2023, and ranking in the top half of its field within Scopus metrics. Although currently offered as a subscription-based journal, Infectious Microbes & Diseases significantly enriches its disciplines by inviting innovative research and critical review articles, thus playing a vital role in combating the global challenges posed by infectious diseases.

Antimicrobial Resistance and Infection Control is a leading open access journal published by BMC, dedicated to the dissemination of research in the critical area of antimicrobial resistance and its impact on infection control practices. Since its inception in 2012, the journal has quickly established itself as a vital resource for researchers, healthcare professionals, and policymakers, featuring a robust array of studies that address the escalating threats posed by antimicrobial resistance across various contexts. With its impressive Q1 rankings across multiple categories—including Infectious Diseases, Microbiology, Pharmacology, and Public Health—the journal’s influence is underscored by its consistent placement in the upper echelons of academic research. Furthermore, it holds commendable ranks in Scopus, with percentiles placing it in the top tier of its respective fields. The journal serves as an essential platform for innovative research and discussions aimed at curbing the threats of antimicrobial resistance, thereby supporting the global health community in striving for effective solutions to safeguard public health.

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, published by Cambridge University Press, is a leading academic journal specializing in the critical fields of epidemiology, infectious diseases, and medical microbiology. With a history of publication dating back to 1988 and an expected continuation through 2024, the journal has established itself as a pivotal resource for researchers, healthcare professionals, and students alike. The journal's impact is reflected in its impressive rankings, positioning it in the second quartile for Epidemiology and the first quartile for both Infectious Diseases and Medical Microbiology as of 2023. This esteemed journal is dedicated to the dissemination of high-quality research that informs best practices in infection control and enhances patient safety across healthcare settings. Although access to its content is not open, the rigorous peer-review process ensures that all published articles contribute significantly to the body of knowledge in these vital areas. With a commitment to bridging the gap between research and practice, INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY remains an essential publication for those committed to the advancement of public health and the science of infection prevention.

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA is a prominent journal dedicated to the fields of infectious diseases and clinical microbiology, published by EDICIONES DOYMA S A in Spain. With an ISSN of 0213-005X and an e-ISSN of 1578-1852, the journal has been a cornerstone of research and scholarly communication since its inception in 1989. As of 2023, it holds a Q3 category ranking in Infectious Diseases, highlighting its significance in the field, alongside a Q4 ranking in the related area of Microbiology. Although the journal is not open access, it remains an essential resource for professionals, researchers, and students aiming to stay informed on advancements and studies that impact clinical practices in infectious diseases. With Scopus ranks indicating a percentile ranking in the 20th to 34th range across various sub-disciplines, ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA continually contributes to the dialogue and development of science, fostering a deeper understanding of complex microbial interactions and disease mechanisms.

CLINICAL MICROBIOLOGY AND INFECTION is a leading journal published by Elsevier Science Ltd, dedicated to advancing the field of infectious diseases and clinical microbiology. With its ISSN 1198-743X and E-ISSN 1469-0691, this esteemed journal has maintained its influential presence since 1995, showcasing high-impact research that addresses critical issues in the diagnosis, treatment, and prevention of infections. Ranked in the Q1 quartile for Infectious Diseases, Medicine (miscellaneous), and Microbiology (medical) categories, and boasting impressive Scopus rankings of #12 and #7 respectively, it sits at the forefront of scientific inquiry in these disciplines. Although it is not an Open Access journal, it provides comprehensive access options for institutions and individuals, ensuring the dissemination of vital research findings. As the field of clinical microbiology continues to evolve, CLINICAL MICROBIOLOGY AND INFECTION remains an essential resource for researchers, clinicians, and students aiming to stay informed on the latest developments and breakthroughs in understanding infectious diseases.

New Microbes and New Infections is an esteemed peer-reviewed journal published by Elsevier Sci Ltd that has been a prominent platform for disseminating groundbreaking research in the fields of Infectious Diseases and Microbiology since its establishment in 2013. With an impressive Open Access model, this journal ensures that vital research findings are readily accessible to researchers, healthcare professionals, and academics worldwide. Positioned in the Q2 category for Infectious Diseases and Q3 for Microbiology in 2023, it reaches a significant global audience, as demonstrated by its high Scopus rankings—#44 out of 344 in Medicine: Infectious Diseases, and #34 out of 182 in Immunology and Microbiology. The journal aims to inspire new ideas and foster collaborations by publishing high-quality research focused on novel microbes and infections, thus playing a crucial role in advancing science and public health in an era where understanding infectious agents is more vital than ever.

International Journal of Antimicrobial Agents, published by Elsevier, stands as a premier platform in the fields of Infectious Diseases, Microbiology, and Medical Pharmacology. With an impressive impact factor and ranked in the Q1 category across multiple medical disciplines in 2023, this journal is recognized for its contribution to advancing knowledge and understanding in the efficacy and safety of antimicrobial treatments. Its comprehensive scope from 1991 to 2024 allows for the publishing of original research, reviews, and commentary on pressing issues related to antimicrobial resistance, treatment strategies, and pharmacological innovations. With a strong emphasis on high-quality research as reflected in its Scopus rankings, the journal is an essential resource for researchers, clinicians, and students dedicated to improving patient outcomes in the face of evolving microbiological challenges. Engage with the latest findings and methodologies through this vital academic resource, available in print and online, from the heart of the Netherlands.

LANCET INFECTIOUS DISEASES is a premier journal published by Elsevier Science Ltd, dedicated to disseminating high-quality research and comprehensive reviews in the field of infectious diseases. Since its inception in 2001, the journal has become a pivotal resource in the medical community, recognized for its rigorous peer-review process and impactful contributions to public health. With an impressive Scopus rank of #2 out of 344 in the category of Medicine - Infectious Diseases, it consistently ranks in the 99th percentile, highlighting its importance and influence in shaping clinical and epidemiological research. The journal's commitment to advancing knowledge in infectious diseases is underscored by its Q1 quartile designation in 2023, affirming its status as a leading academic outlet. Although not an open-access journal, LANCET INFECTIOUS DISEASES provides essential insights for researchers, healthcare professionals, and students, bridging the gap between cutting-edge research and practical application in an increasingly interconnected world.